Abetis 10 tablet: Each coated tablet contains Olmesartan Medoxomil USP 10 mg.
Abetis 20 tablet: Each coated tablet contains Olmesartan Medoxomil USP 20 mg.
Abetis 40 tablet: Each coated tablet contains Olmesartan Medoxomil USP 40 mg.
Abetis is the preparation of Olmesartan Medoxomil which is a selective AT 1 subtype angiotensin II receptor antagonist. Olmesartan Medoxomil blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis.
Route: Oral (with or without food)
Adult hypertension:
20 mg once daily; titrate to 20 to 40 mg once daily if needed. Diuretic or other antihypertensives may be added.
Pediatric hypertension (≥6 years):
Children <1 year must not receive olmesartan; not established in children <6 years.
Hepatic impairment:
Maximum dose is 20 mg daily in moderate hepatic impairment. Not recommended in severe hepatic impairment.
Renal impairment:
Maximum dose is 20 mg daily if eGFR 20–60 mL/min/1.73 m². Not recommended in severe renal impairment.
Potassium-sparing diuretics, potassium supplements, or salt substitutes increase hyperkalemia risk; NSAIDs attenuate antihypertensive effect and increase renal impairment risk; aliskiren increases hypotension and hyperkalemia risk; bile acid sequestrants reduce bioavailability.
Hypersensitivity to olmesartan medoxomil or any component of the formulation; co-administration with aliskiren in patients with diabetes or renal impairment (eGFR <60 mL/min/1.73 m²).
Common: Headache, influenza-like symptoms, dizziness.
Overdose
In case of overdose, hypotension and tachycardia; bradycardia could be encountered if parasympathetic stimulation occurs. If symptomatic hypotension occurs, initiate supportive treatment. The dialyzability of olmesartan medoxomil is unknown.
Category D (2nd/3rd trimesters), Category C (1st trimester). Drugs acting on the renin-angiotensin system reduce fetal renal function and increase fetal and neonatal morbidity and death; discontinue immediately when pregnancy is detected. Lactation: Excretion in human milk is unknown; discontinue nursing or discontinue drug.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.